Xinying Zhu, Gongli Zhou, Ying Zhou, Chen Chen, Lin Sui, Di Ou, Yuqi Yan, Lingyan Zhou, Zhiyan Jin, Jiaheng Huang, Yin Zheng, Chen Ni, Min Lai, Lujiao Lv, Jiafei Shen, Fang Cheng, Xiangkai Kong, Xuefeng Zhang, Ke Xu, Ruiqing Su, Ying Liu, Gang Dong, Shurong Wang, Minghua Ge, Dong Xu
{"title":"Early efficacy of radiofrequency ablation for multifocal T1N0M0 papillary thyroid carcinoma: a multicenter study.","authors":"Xinying Zhu, Gongli Zhou, Ying Zhou, Chen Chen, Lin Sui, Di Ou, Yuqi Yan, Lingyan Zhou, Zhiyan Jin, Jiaheng Huang, Yin Zheng, Chen Ni, Min Lai, Lujiao Lv, Jiafei Shen, Fang Cheng, Xiangkai Kong, Xuefeng Zhang, Ke Xu, Ruiqing Su, Ying Liu, Gang Dong, Shurong Wang, Minghua Ge, Dong Xu","doi":"10.1080/02656736.2025.2482716","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the efficacy and safety of radiofrequency ablation (RFA) for multifocal papillary thyroid carcinoma (M-PTC) and compare these outcomes with those for unifocal papillary thyroid carcinoma (U-PTC).</p><p><strong>Methods: </strong>This retrospective multicenter study included 465 patients (367 women and 98 men) who underwent RFA for either U-PTC (411 patients) or M-PTC (54 patients) between May 2015 and October 2022. Patients were followed up at 1, 3, 6, and 12 months post-RFA, then every 6 months in the second year, and annually thereafter. After 1:1 propensity score matching (PSM), local tumor progression rate (LTP), tumor volume, volume reduction rate (VRR), tumor complete response rate (CDR), and complications were evaluated and compared between the M-PTC and U-PTC groups during the follow-up period.</p><p><strong>Results: </strong>The median follow-up time was 23 months. The median follow-up time for the U-PTC and M-PTC groups was 23 months and 23.5 months, respectively. The overall local tumor progression rate was 0.9% (4/465), and the overall complication rate was 0.6% (3/465). After PSM, no significant differences were observed between the U-PTC and M-PTC groups regarding tumor volume (<i>p</i> = 0.377), VRR (<i>p</i> = 0.151), CDR (50% vs. 44.2%, <i>p</i> = 0.556), or LTP (1.9% vs. 0%, <i>p</i> = 0.556). Additionally, the complication rates were not significantly different between the groups (1.03% vs. 2.5%, <i>p</i> = 0.343).</p><p><strong>Conclusion: </strong>After adequate preoperative evaluation, RFA is an effective and safe treatment for appropriately selected patients with M-PTC, with a prognosis similar to that of U-PTC.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2482716"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hyperthermia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02656736.2025.2482716","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study aimed to assess the efficacy and safety of radiofrequency ablation (RFA) for multifocal papillary thyroid carcinoma (M-PTC) and compare these outcomes with those for unifocal papillary thyroid carcinoma (U-PTC).
Methods: This retrospective multicenter study included 465 patients (367 women and 98 men) who underwent RFA for either U-PTC (411 patients) or M-PTC (54 patients) between May 2015 and October 2022. Patients were followed up at 1, 3, 6, and 12 months post-RFA, then every 6 months in the second year, and annually thereafter. After 1:1 propensity score matching (PSM), local tumor progression rate (LTP), tumor volume, volume reduction rate (VRR), tumor complete response rate (CDR), and complications were evaluated and compared between the M-PTC and U-PTC groups during the follow-up period.
Results: The median follow-up time was 23 months. The median follow-up time for the U-PTC and M-PTC groups was 23 months and 23.5 months, respectively. The overall local tumor progression rate was 0.9% (4/465), and the overall complication rate was 0.6% (3/465). After PSM, no significant differences were observed between the U-PTC and M-PTC groups regarding tumor volume (p = 0.377), VRR (p = 0.151), CDR (50% vs. 44.2%, p = 0.556), or LTP (1.9% vs. 0%, p = 0.556). Additionally, the complication rates were not significantly different between the groups (1.03% vs. 2.5%, p = 0.343).
Conclusion: After adequate preoperative evaluation, RFA is an effective and safe treatment for appropriately selected patients with M-PTC, with a prognosis similar to that of U-PTC.
目的：本研究旨在评估射频消融（RFA）治疗多灶性甲状腺乳头状癌（M-PTC）的有效性和安全性，并将这些结果与单灶性甲状腺乳头状癌（U-PTC）的结果进行比较。方法：这项回顾性多中心研究纳入了465例患者（367名女性和98名男性），这些患者在2015年5月至2022年10月期间接受了U-PTC（411例）或M-PTC（54例）的RFA。患者在rfa后1、3、6和12个月随访，第二年每6个月随访一次，此后每年随访一次。经1:1倾向评分匹配（PSM），评估并比较M-PTC组与U-PTC组随访期间局部肿瘤进展率（LTP）、肿瘤体积、体积缩小率（VRR）、肿瘤完全缓解率（CDR）及并发症。结果：中位随访时间为23个月。U-PTC组和M-PTC组的中位随访时间分别为23个月和23.5个月。整体局部肿瘤进展率为0.9%(4/465)，整体并发症率为0.6%（3/465）。PSM后，U-PTC组与M-PTC组在肿瘤体积（p = 0.377）、VRR （p = 0.151）、CDR （50% vs. 44.2%, p = 0.556）或LTP （1.9% vs. 0%, p = 0.556）方面均无显著差异。并发症发生率组间比较差异无统计学意义（1.03% vs. 2.5%, p = 0.343）。结论：经术前充分评估，选择适当的M-PTC患者，RFA是一种安全有效的治疗方法，预后与U-PTC相似。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
